P/E ratio for Zoetis (ZTS)
P/E ratio as of April 2024 (TTM): 30.9
According to Zoetis's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 30.8821. At the end of 2022 the company had a P/E ratio of 32.5.
P/E ratio history for Zoetis from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 32.5 | -42.74% |
| 2021 | 56.8 | 17.96% |
| 2020 | 48.1 | 14.14% |
| 2019 | 42.1 | 45.36% |
| 2018 | 29.0 | -29.16% |
| 2017 | 40.9 | 26.17% |
| 2016 | 32.4 | -53.96% |
| 2015 | 70.5 | 89.97% |
| 2014 | 37.1 | 14.61% |
| 2013 | 32.4 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 13.7 | -55.75% | 🇺🇸 USA |
 Eli Lilly LLY | 138 | 347.77% | 🇺🇸 USA |
 Sanofi SNY | 14.5 | -53.05% | 🇫🇷 France |
 Merck MRK | 68.8 | 122.85% | 🇺🇸 USA |
 Phibro Animal Health
PAHC | 18.1 | -41.30% | 🇺🇸 USA |
 Kindred Biosciences
KIN | N/A | N/A | 🇺🇸 USA |
 Heska Corporation
HSKA | -62.2 | -301.32% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.